• Mashup Score: 0
    Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 | Vincerx Pharma - 8 month(s) ago

    Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL PALO ALTO, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through

    Source: investors.vincerx.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 First patient dosed in a phase I study of VIP943, a novel CD123 antibody-drug conjugate, to assess the safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in patients with R/R AML, MDS, or B-cell ALL. https://t.co/ptucEyk7lz. #AMLsm #leusm #MedNews https://t.co/XmDlyf0uVw

  • Mashup Score: 2
    Vincerx Pharma Announces FDA Clearance of IND for VIP943 | Vincerx Pharma - 9 month(s) ago

    Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif. , Aug. 22, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc.

    Source: investors.vincerx.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 @US_FDA gives clearance to an Investigational New Drug application to initiate the phase I clinical trial of VIP943, a CD123-targeting antibody-drug conjugate, for the treatment of patients with advanced AML and MDS. https://t.co/ccDytDKdTW. #leusm #AMLsm #MedNews https://t.co/xvLVu4jMfi